新华财经北京12月10日电（胡晨曦）科创50指数12月10日早间低开，指数早盘持续调整，午后指数有所 反弹，尾盘时短暂翻红但力度不强，最终以微跌报收。至收盘时，科创50指数报1346.7点，跌幅 0.03%，指数振幅为2.45%，总成交额约553.6亿元。 12月10日，科创综指全日收涨0.14%，收于1604.56点，总成交额1803亿元。 个股表现方面，不考虑上市首日的百奥赛图，霍莱沃涨停，涨幅居首；佳华科技跌10.1%，跌幅居首。 成交额方面，摩尔线程成交额108.2亿元，位居首位；汉邦科技成交额731.4万元，位居末位。 换手率方面，不考虑上市首日的百奥赛图，摩尔线程换手率为51.93%，位居首位；中复神鹰换手率为 0.14%，位居末位。 （文章来源：新华财经） 从盘面来看，科创板595只个股涨少跌多，高价股表现分化，低价股则多数下跌。细分领域来看，半导 体股、通信设备股表现强势，电气设备股、软件服务股跌幅靠前；专用机械股表现分化。 百奥赛图12月10日在上交所科创板上市，公司证券代码为688796，发行价格26.68元／股，发行市盈率 为519.12倍。百奥赛图是一家主要从事药物开发业务及临床前研究 ...

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].